Showing results (761-770 of 1,074) with videos related to

Sort By:
Pageof 108
JACC. Cardiovascular Interventions|August 23, 2023
Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) StudyFrancesco Franchi, Fabiana Rollini, Luis Ortega-Paz, et al.
Circulation|February 8, 2021
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 UpdateDominick J Angiolillo, Deepak L Bhatt, Christopher P Cannon, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 30, 2022
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapyMattia Galli, Francesco Franchi, Fabiana Rollini, et al.
Thrombosis and Haemostasis|August 31, 2019
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT StudyFrancesco Franchi, Fabiana Rollini, Emilio Garcia, et al.
Circulation|December 7, 2007
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trialStephen D Wiviott, Dietmar Trenk, Andrew L Frelinger, et al.
JACC. Cardiovascular Interventions|February 11, 2026
Genotype-Guided vs Conventional Oral P2Y12 Inhibitors in Acute Coronary Syndrome: A Combined Analysis of TAILOR-PCI and POPular GeneticsMattia Galli, Naveen L Pereira, Ryan J Lennon, et al.
Thrombosis and Haemostasis|January 4, 2022
Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic DiseaseMattia Galli, Francesco Franchi, Fabiana Rollini, et al.
Lancet (London, England)|September 3, 2025
Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysisMarco Valgimigli, Ki Hong Choi, Daniele Giacoppo, et al.
JAMA|January 19, 2012
Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trialDominick J Angiolillo, Michael S Firstenberg, Matthew J Price, et al.
Blood Advances|March 29, 2018
Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarctionOliver Borst, Patrick Münzer, Nada Alnaggar, et al.
Pageof 108